Trial Profile
A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Bevacizumab; Irinotecan
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 May 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
- 11 Dec 2012 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov record.